Kanishk Kumar: TFPI Market Size – Advancing Hemostasis and Antithrombotic Therapy
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, posted on LinkedIn:
”Tissue Factor Pathway Inhibitors (TFPI) Market: Advancing Hemostasis and Antithrombotic Therapy
Tissue Factor Pathway Inhibitors (TFPIs) are emerging as a novel class of anticoagulants, offering targeted approaches to manage thrombotic disorders with potentially improved safety profiles compared to conventional therapies. As cardiovascular and thrombotic disease burdens rise globally, TFPI-based therapies are gaining attention for their role in precision medicine. Despite challenges like clinical development complexity and regulatory pathways, the TFPI market shows strong potential for innovation.
DelveInsight’s report – TFPI Market Size, Target Population, Competitive Landscape and Market Forecast – 2034 – provides:
– Comprehensive epidemiological analysis across major markets
– Current and emerging therapeutic strategies, including recombinant proteins, monoclonal antibodies, and fusion molecules
– Pipeline landscape with novel candidates and ongoing clinical trials
– Market dynamics – key drivers, barriers, and opportunities shaping TFPI adoption
– Competitive landscape highlighting leading pharmaceutical and biotechnology innovators
Key Players in the TFPI Companies space include Bayer, Novo Nordisk, Sanofi, Pfizer, Bristol Myers Squibb, CSL , Shire, Alnylam Pharmaceuticals, and others.
With ongoing R&D, growing patient populations, and global initiatives to improve thrombotic care, the TFPI market is poised for significant growth and innovation through 2034.
Access the full report here.”
Stay updated with Hemostasis Today.
-
Oct 3, 2025, 07:53Pancytopenia in Pregnancy: A Time-Critical Hematological Emergency
-
Oct 2, 2025, 14:12Helen McPherson at ISFP-IFRS 2025: Fibrin Clot Structure and Function Modulation by Targeting Fibrinogen aC Region
-
Oct 2, 2025, 10:48Kanishk Kumar: TFPI Market Size - Advancing Hemostasis and Antithrombotic Therapy
-
Oct 2, 2025, 07:31Non-Invasive Management of Radial Artery Pseudoaneurysm
-
Oct 2, 2025, 07:28Mohamed Gamal: Rethinking The Standard of Care for Deep Vein Thrombosis Management
-
Oct 3, 2025, 14:00Quentin Van Thillo Shares His Latest Article on VWD: Grateful to Have Worked with Cedric Hermans
-
Oct 3, 2025, 13:40Cihan Ay and Colleagues on Thromboembolism and Bleeding in Multiple Myeloma
-
Oct 3, 2025, 13:27Laura Haynes: This Was Such a Fun and Collaborative Project to Be a Part of!
-
Oct 3, 2025, 12:40Christian Pfrepper and Team's Letter on Emicizumab Plasma Concentration Measurment in EDTA plasma
-
Oct 3, 2025, 12:00Giuseppe Lippi and Colleagues on the Impact of Hemolysis on Coagulation Testing
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 3, 2025, 14:48Maha Othman - Elected as the Co-Lead for the Basic and Translational Research Platform at CanVECTOR Research Network
-
Oct 3, 2025, 14:41Maria Elisa Mancuso: A Real Pleasure to Participate in The Policy Roundtable on Future of Haemophilia Care in Egypt
-
Oct 2, 2025, 04:37Louise Bannon: Did You Know that 1 in 4 People Lose Their Lives to Blood Clot-Related Conditions?
-
Oct 1, 2025, 16:35World Thrombosis Day 2025․ 8 Ways to Take Control and Save Lives
-
Oct 1, 2025, 12:30World Stroke Academy "Antithrombotic Therapy for Atherosclerotic Stroke Prevention" Webinar is Now Available to Record